-
1
Outcomes of relapsed/refractory patients with IDH1/2 mutated AML treated with non-targeted therapy: results from the NCRI AML trials
Published 2018“…American Society of Hematology…”
Conference item -
2
Molecular MRD status and outcome after transplantation in NPM1-mutated AML
Published 2020“…American Society of Hematology…”
Journal article -
3
No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials
Published 2018“…American Society of Hematology…”
Journal article -
4
Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia
Published 2016“…American Society of Hematology…”
Journal article -
5
CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML
Published 2018“…American Society of Hematology: Blood Advances…”
Journal article